Investors

Company Profile

Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.

Financial Reports

Q3 Report 2021

November 4, 2021

Q2 Half Year Report 2021

August 5, 2021

Q1 Report 2021

May 6, 2021

Investor presentations

Linzagolix Phase 3 PRIMROSE 2 Trial Results

Investor Presentation 10th Annual Jefferies Global Healthcare Conference 21 November 2019

Investor Presentation November 2019

Cantor Global Healthcare Conference October 4 2019

The H.C. Wainwright 21st Annual Global Investment in NYC – September 10th 2019

Wedbush Presentation August 2019 in NYC

KOL Event in NYC July 2019

Jefferies Healthcare Conference Presentation – June 2019

1 2 3 4 5

Press Releases

Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix

press release

November 22, 2021

FDA Accepts NDA for Linzagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids Ad hoc announcement pursuant…

Read more

Obseva Announces Appointment of Stephanie Brown to its Board of Directors

press release

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland November 22, 2021 – ObsEva…

Read more

ObsEva Announces Third Quarter 2021 Financial Results and Business Update

press release

November 4, 2021

-Linzagolix for uterine fibroids: Pending regulatory approval in the US and Europe with commercial planning efforts underway- -Linzagolix for endometriosis:…

Read more
1 2 3 67

General Meetings

ObsEva Annual General Meeting 2019

May 8, 2019

Read more

ObsEva Annual General Meeting 2018

May 9, 2018

Read more
1 2 3

Upcoming Events

Sorry, there are no events available yes.

 

Contacts

ObsEva Switzerland Office

Chemin des Aulx,12

1228, Plan-Les-Ouates, Geneva, Switzerland

+41 (0)22 552 3840


contact@obseva.ch

Media

Shauna Dillon

+41 (0)22 552 1550 Office

+41 79 360 3533 Mobile

shauna.dillon@obseva.ch

Investor relations


.


Joyce Allaire

+1 (617)-435-6602

ir@obseva.ch

Clinical studies




clinicaltrials@obseva.ch

HR Office

Charlotte Cadoux


charlotte.cadoux@obseva.ch

CEO Office

+41 (0)22 552 1550


shauna.dillon@obseva.ch

 

Sign up for news

 
 

    * Type:


    InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












    Read our privacy policy here.


     

    Are you sure you want to leave ObsEva.com?

    We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

    Continue to link

    Disclaimer

    Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

    Continue

    Disclaimer

    Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

    Continue